cross-referenced news and research resources about

 Johnson & Johnson logo
images:  google   yahoo YouTube

updated Mon. October 24, 2016 reload page to refresh

You might think that there are probably few healthcare companies that have less in common than Intuitive Surgical (Nasdaq:ISRG) and Johnson & Johnson (nyse:JNJ). Intuitive Surgical is best known for its da Vinci robotic surgery systems. J&J is probably ...
The New Jersey-based Johnson & Johnson will play an active role in the project by assisting the state government in achieving the goal.

The key products for Johnson & Johnson's cardiovascular and metabolics franchise are Xarelto and Invokana. The revenues for both of these drugs are expected to rise in 3Q16 following an increased demand for them in US markets.
investors are always looking for stocks that are poised to beat at earnings season and Johnson & Johnson (JNJ - Free Report) may be one such company.
For 2016, we expect Johnson & Johnson to maintain its full-year guidance of 6% organic sales growth (6.5% adjusted for prior year's extra selling week) and reported EPS of $6.53-$6.68.
In the healthcare sector, conglomerate Johnson & Johnson (nyse:JNJ), the largest publicly traded company in healthcare, has the pleasure of leading things off each quarter.

This year, Johnson & Johnson JNJ, -0.59% has generally performed favorably compared with 2015, when revenue growth decelerated in the face of competition for its hepatitis C drug and earnings declined, according to J.P.
In the upcoming weeks, I'll be reviewing the 18 Kings. Today, I will analyze Johnson & Johnson (nyse:JNJ). Since I've already done a lengthy analysis on Seeking Alpha (you can read it here), I will concentrate on JNJ dividend payment future perspectives.
Could J&J's recent news about its rheumatoid arthritis and Crohn's disease drugs threaten AbbVie's Humira?
Most people know healthcare giant Johnson & Johnson (nyse: JNJ) because of the over-the-counter brands that they have in their medicine cabinets.
Above $120, he would make money on the call option and he would lose money if Johnson & Johnson trades below $114.65 at the January expiration.
As a rule of thumb I try to limit my exposure to one stock per industry. For quite some time I've been a fan of medical conglomerate Johnson & Johnson (nyse:JNJ), I first wrote about it back in April 2015, but I've been long the stock since 2009 ...
Johnson & Johnson's Animas OneTouch Ping insulin pump can be hacked by anyone within 25 feet of the user. With the right radio equipment, a hacker can take control of the pump and trigger unauthorized insulin injections.
A Rapid7 researcher found out that Johnson & Johnson Animas' Insulin Pumps can be hacked where attackers can increase the patient's regular insulin dose, making it an overdose.
With this article, I'm going to share my specific process on how I estimate the future return that a stock can be expected to offer me.

healthcare conglomerate Johnson & Johnson (nyse:JNJ) probably needs little introduction -- it's a commonly held stock among long-term investors, income seekers, and retirees.
Elizabeth Ross "Libet" Johnson, a Johnson & Johnson heiress with an appetite for high-end real estate, is selling her Millbrook, New York, horse farm, The Wall Street Journal reported.
Johnson & Johnson (NYSE:JNJ) went down -0.54% during trading on 9/23/2016, hitting $119.60. The stock had a trading volume of 4.8 M shares.
Johnson & Johnson currently has a total float of 2.74 billion shares and moves 6.46 million a day, on average. The stock opened at $118.63 on September 26 and traded between a low of $117.56 and a high of $118.64.
Johnson & Johnson (nyse:JNJ) started a downward trend just as the month of August started. This significant stock price movement pushed shares lower over the past 6 weeks.
Johnson & Johnson (nyse: JNJ) is often not very vocal about receiving drug approvals, at least not using its own name. Janssen Biotech, a unit of Johnson & Johnson's Janssen companies, has announced that the U.S. Food and Drug Administration (FDA) ...
After settling with two cases on similar allegations, Johnson & Johnson is yet again faced with another lawsuit involving its baby powder being linked to cancer.
The medical products giant announced a $4.3 billion agreement to buy Abbott Medical optics, a deal that adds $1.1 billion in annual sales and three ophthalmic products to its Johnson & Johnson Vision Care Inc. division. Before this expansion, J&J ...
healthcare and pharmaceutical giant Johnson & Johnson is considering commercialising two of the winning inventions from a hackathon earlier this month, which would result in faster rehabilitation for people who have had knee reconstructions, and better ...
Dow Jones component Johnson & Johnson (JNJ) saw its stock move -0.54% to $118.81, representing a per-share move of $0.65, on volume of 4.73 million shares for Friday.
Among the large investment banks, Morgan Stanley gave Johnson & Johnson a one-year target price of $128, which implies a ~7.1% return potential during the next 12 months.
One year on since the adoption of the Sustainable Development Goals, and a year since Johnson & Johnson joined RE100 at Climate Week NYC 2015, Paulette Frank, Vice President, Environment, Health, Safety & Sustainability at Johnson & Johnson, ...
Acclarent, a subsidiary of Johnson & Johnson (JNJ), launched its Acclarent Aera system in the US on September 19, 2016.
Johnson & Johnson (nyse:JNJ) remained bullish with an increase +0.46% putting the price on the $119.46 per share in last trading session ended on 9/22/2016.
Among the top participants in big PhaRMA are Pfizer (nyse:PFE) and Johnson & Johnson (NYSE:JNJ), and although J&J's business has a much larger scope that fully incorporates other products like medical devices and over-the-counter consumer health ...
Just as August began, Johnson & Johnson ( JNJ) entered a pullback stage. This healthy action carried shares steadily lower over the last six weeks. reports on a recent effort by Johnson & Johnson to have claims of fraud and conspiracy dismissed. An Aug. 23 motion by the company ...
Janssen pharmaceuticals, a subsidiary of the giant manufacturing company, Johnson & Johnson (nyse:JNJ) has expanded the current partnership with the long-beleaguered Geron corporation (Nasdaq:GERN).
This time last year, I was somewhat skeptical of growth prospects for Johnson & Johnson (nyse:JNJ). Don't get me wrong, the company's strong brand and dividend would not have allowed me to sell easily, but I was concerned as to whether this company ...
If you're looking for a blue chip stock with a stellar track record of dividend hikes, you're bound to keep bumping into Procter & Gamble (nyse:PG) and Johnson & Johnson (NYSE:JNJ) as investment candidates. After all, between them they boast dominant ...
Johnson & Johnson's cash returns are smaller, at $13.5 billion last year. However, the healthcare giant does have P&G beat in the area of dividend growth.
Surgical robotics company Intuitive Surgical's (Nasdaq:ISRG) near-monopoly is facing a threat from two of America's most powerful companies, Alphabet's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google and Johnson & Johnson (nyse:JNJ). The corporate ...
Johnson & Johnson (nyse:JNJ) went down -0.50% during trading on 9/19/2016, hitting $118.66. The stock had a trading volume of 5.5 M shares.
Johnson & Johnson (JNJ) is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.
healthcare conglomerate Johnson & Johnson (nyse:JNJ), the largest publicly traded healthcare company in the U.S., has been patiently on the prowl for acquisitions for more than a year.
Johnson & Johnson (nyse:JNJ) reported its last earnings on Oct 18 BMO (BMO = before market open, AMC= after market close).
Roffman Miller Associates Inc. PA lowered its position in Johnson & Johnson (nyse:JNJ) by 3.0% during the second quarter, according to its most recent Form ...
Johnson & Johnson logo Neville Rodie & Shaw Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the SECond quarter, according to its most recent disclosure with the SEC.
NEW YORK (TheStreet) -- Shares of Johnson & Johnson (JNJ) were decreasing in early-afternoon trading on Friday as the New Brunswick, NJ-based medical devices, pharmaceutical and packaged goods manufacturer is buying 100 megawatts from a ...
Johnson & Johnson's Ashley McEvoy said the acquisition was a way to become "a more broad-based leader in vision care," and described eye health as a large, quickly-growing and underserved health care segment.
Johnson & Johnson announced Friday that it has offered Abbott Laboratories $4.325 billion in cash for eye health unit Abbott Medical optics.
Johnson & Johnson's (nyse:JNJ) share price has surged by almost 14% since the start of this year and soared by nearly 26% in the trailing twelve months.





     johnson & johnson

consumer corporations:
     avon products
     del monte
     estee lauder
     fast food
     johnson & johnson
     kraft foods
     rite aid
     united brands